Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Sell
47
DARE Quote, Financials, Valuation and Earnings
Last price:
$2.80
Seasonality move
:
-15.23%
Day range:
$2.94 - $2.98
52-week range:
$2.67 - $7.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,543.96x
P/B ratio:
11.45x
Volume:
4.3K
Avg. volume:
16.2K
1-year change:
-20.41%
Market cap:
$26.4M
Revenue:
$9.8K
EPS (TTM):
-$0.62
Analysts' Opinion
-
Consensus RatingDare Bioscience has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.33, Dare Bioscience has an estimated upside of 347.43% from its current price of $2.98.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $2.98.
Fair Value
-
According to the consensus of 3 analysts, Dare Bioscience has 347.43% upside to fair value with a price target of $13.33 per share.
DARE vs. S&P 500
-
Over the past 5 trading days, Dare Bioscience has underperformed the S&P 500 by -3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Dare Bioscience does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dare Bioscience has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Dare Bioscience reported revenues of $41.7K.
Earnings Growth
-
Dare Bioscience has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Dare Bioscience reported earnings per share of -$0.55.
Enterprise value:
10.7M
EV / Invested capital:
--
Price / LTM sales:
2,543.96x
EV / EBIT:
--
EV / Revenue:
1,091.17x
PEG ratio (5yr expected):
--
EV / Free cash flow:
2.21x
Price / Operating cash flow:
5.16x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-17.84%
Net Income Margin (TTM):
-191.61%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-11228.68%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $9.8K | $1.8M | -$63.7K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$31.4M | -$30.9M | -$23.5M | -$5.2M | -$5.4M | |
| EBITDA | -$31.4M | -$30.9M | -$23.4M | -$5.2M | -$5.4M | |
| Diluted EPS | -$4.38 | -$4.09 | -$0.52 | -$0.70 | -$0.65 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7M | $55.3M | $43M | $17.5M | $18.4M | |
| Total Assets | $7.6M | $55.8M | $43.8M | $21.3M | $22.1M | |
| Current Liabilities | $7.7M | $16.1M | $31.6M | $20.5M | $21.6M | |
| Total Liabilities | $8.7M | $17.1M | $32.7M | $26.3M | $28.1M | |
| Total Equity | -$1.2M | $38.8M | $11.1M | -$5M | -$6M | |
| Total Debt | $367.3K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$18.1M | -$38.9M | $5.4M | -$8.2M | $5.2M | |
| Cash From Investing | -$63.1K | -$629.4K | -$573K | -$607.3K | -$562.9K | |
| Cash From Financing | $1.3M | $15.6M | $433.8K | $5.3M | -$132K | |
| Free Cash Flow | -$18.2M | -$39.5M | $4.8M | -$8.8M | $4.7M | |
DARE
Sector
Market Cap
$26.4M
$35.8M
Price % of 52-Week High
39.42%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
-4.28%
-0.81%
1-Year Price Total Return
-20.41%
-38.89%
Beta (5-Year)
1.196
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.96
200-day SMA
Sell
Level
$3.29
Bollinger Bands (100)
Sell
Level
2.91 - 3.25
Chaikin Money Flow
Sell
Level
-35.3M
20-day SMA
Buy
Level
$2.94
Relative Strength Index (RSI14)
Buy
Level
53.96
ADX Line
Buy
Level
29.46
Williams %R
Neutral
Level
-47.0588
50-day SMA
Buy
Level
$2.96
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
55.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.1972)
Sell
CA Score
(Annual)
Level (-8.8056)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (11.2229)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women’s health.
Stock Forecast FAQ
In the current month, DARE has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The DARE average analyst price target in the past 3 months is $13.33.
-
Where Will Dare Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dare Bioscience share price will rise to $13.33 per share over the next 12 months.
-
What Do Analysts Say About Dare Bioscience?
Analysts are divided on their view about Dare Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dare Bioscience is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Dare Bioscience's Price Target?
The price target for Dare Bioscience over the next 1-year time period is forecast to be $13.33 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is DARE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dare Bioscience is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DARE?
You can purchase shares of Dare Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dare Bioscience shares.
-
What Is The Dare Bioscience Share Price Today?
Dare Bioscience was last trading at $2.80 per share. This represents the most recent stock quote for Dare Bioscience. Yesterday, Dare Bioscience closed at $2.98 per share.
-
How To Buy Dare Bioscience Stock Online?
In order to purchase Dare Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
